

Literature Summary on Uses of AmnioGraft in Ocular Surface Reconstruction

(By Dr. Scheffer CG Tseng)

I. Introduction

II. Action Mechanisms

III. Clinical Uses

1. As a Temporary Graft (Patch, Dressing, or Bandage)

2. As a Permanent Graft

A. For Corneal Surface Reconstruction

- 1) Corneal Ulcers with Different Depths Including Perforation**
- 2) Symptomatic Bullous Keratopathy**
- 3) Band Keratopathy**
- 4) Partial Limbal Stem Cell Deficiency**

B. For Conjunctival Surface Reconstruction

- 1) Conjunctivochalasis**
- 2) Tumors**
- 3) Glaucoma Surgery / Leaking Bleb**
- 4) Scleral Melt**
- 5) Pterygium**
- 6) Symblepharon and Fornix Reconstruction**
- 7) Miscellaneous**

C. For Both Corneal and Conjunctival Surface Reconstruction

D. In Conjunction with Other Surgical Procedures

- 1) With Conjunctival Limbal Autograft or Allograft**
- 2) With Keratolimbal Allograft**

IV. Complications

V. Other Issues

Literature Summary on Uses of AmnioGraft in Ocular Surface Reconstruction

(By Dr. Scheffer CG Tseng)

I. Introduction

Amniotic membrane, the innermost layer of fetal (or placental) membrane, consists of a simple epithelium, a thick basement membrane and an avascular stroma. Its function is to protect the fetus from unwanted maternal insults during development. It has been recognized that the incision at the skin of the fetus during fetal surgery does not bear any scarring after birth. The phenomenon of “scarless fetal wound healing” remains a mystery^{1,2}. It is tempting to speculate that the amniotic membrane carries the same feature as the fetal tissue in exerting scarless fetal wound healing.

A number of clinical studies have shown that amniotic membrane covered corneal or conjunctival surfaces show rapid epithelialization (i.e., covering of the epithelial cells onto the denuded amniotic membrane) and reduced inflammation, scarring, and unwanted blood vessels. In other words, amniotic membrane facilitates healing and regeneration of cells and tissues with minimal inflammation and scarring [for reviews see^{3-6, 7-11, 12-16} and a recent editorial¹⁷].

II. Action Mechanisms

There are a number of action mechanisms that have been put forth to explain the effectiveness of amniotic membrane used in ocular surface reconstruction. These actions have recently been reviewed¹⁸. They are:

- The amniotic membrane’s basement membrane contains type IV collagen, laminin 1, laminin 5, and collagen VII. Among the six known chains of the collagen IV, the $\alpha 2$ chain is found in human amniotic membrane, a pattern similar to that of the conjunctiva¹⁹, the $\alpha 3$ chain is found in rat amniotic basement membrane²⁰, and the $\alpha 5$ chain of the type IV collagen is found in human amniotic basement membrane^{19, 21}, like that of the corneal epithelial basement membrane. Recently, our laboratory discovered that besides $\alpha 2$ and $\alpha 5$ chains, the human amniotic membrane also express $\alpha 1$ chain (Li et al, manuscript in preparation, 2005). Based on these data, we may conclude that the human amniotic basement membrane contains $[(\alpha 1)_2\alpha 1]$ and $[(\alpha 5)_2\alpha 6]$ triple chains. It has been shown that laminin 5 is important in facilitating corneal epithelial cell adhesion.²² Collagen VII found in human amniotic membrane¹⁹ forms anchoring fibrils that help stabilize epithelial adhesion. Therefore, the basement membrane side of amniotic tissue may be an ideal substrate for supporting the growth of epithelial basal progenitor cells. Epithelial cells, including stem cells, anchor to the basement membrane. Furthermore, the basement membrane facilitates migration of epithelial cells, reinforces adhesion of basal epithelial cells, and promotes epithelial differentiation, and prevent epithelial apoptosis, i.e., programmed cell death^{23, 24}.

- The amniotic membrane's stroma contains unique extracellular matrix components such as fibronectin¹⁹, type I²⁵ and type III collagens²⁶, type IV collagen²⁷, and such glycosaminoglycans/proteoglycans as hyaluronic acid, decorin, and biglycan, and non-glycosylated lumican, which can facilitate epithelial wound healing²⁸. The functions of these matrix proteins remain to be elucidated.
- The amniotic membrane contains several mitogenic growth factors²⁹, several anti-angiogenic and anti-inflammatory proteins³⁰⁻³¹, and natural inhibitors to various serine proteases.³²⁻³⁴ Among mitogenic growth factors, it is particularly intriguing to note that amniotic membrane contains several neurotrophins³⁵ and nerve growth factor (NGF)³⁶, while this tissue is not innervated. The presence of IL-10 in amniotic membrane³⁰⁻³⁷⁻³⁸ may help explain its anti-inflammatory action. The anti-angiogenic action of amniotic membrane may in part be explained by the expression of pigment epithelium derived growth factor (PEDF)³⁹ and endostatin³¹, which is found in the basement membrane and after degradation by MMP, respectively.
- Although the exact molecular candidate(s) in amniotic membrane remains to be elucidated, several experimental studies have demonstrated that amniotic membrane indeed exerts potent anti-inflammatory actions. Expression of IL-1 α and IL-1 β is markedly suppressed when human limbal epithelial cells are cultured on the amniotic membrane stromal matrix, even when challenged by lipopolysaccharide.⁴⁰ When rabbit's corneas receive excimer laser ablation to remove the basement membrane and the superficial stroma in a procedure called superficial keratectomy, known to elicit the least amount of host inflammation. If such a wound is covered by one layer of amniotic membrane, it has been reported that acute inflammation is reduced as evidenced by the rapid apoptosis of polymorphonuclear neutrophils⁴¹⁻⁴². This finding was supported in human patients with acute burns where CD20+ cells are trapped by amniotic membrane and exhibited apoptosis.⁴³ When rabbit's corneas are injured by alkali, amniotic membrane transplantation reduces acute and severe inflammation as evidenced by less amount of infiltration of polymorphonuclear neutrophils.⁴⁴ When rat's corneas are inoculated with HSV-1 (herpes simplex virus type 1) to elicit a severe form of necrotizing keratitis with intense acute and chronic inflammation, it has also been reported that such an inflammation is reduced by covering with one layer of preserved human amniotic membrane for two days⁴⁵. The infiltration of polymorphonuclear neutrophils, lymphocytes, and macrophages is all reduced⁴⁵ with rapid apoptosis (manuscript submitted, 2005). In culture, recently, it has been shown that human amniotic membrane stromal matrix facilitates apoptosis of murine macrophages, especially when they are activated by IFN- γ ⁴⁶. Collectively, the above findings provide evidence to support the anti-inflammatory effect of amniotic membrane transplantation.
- Although the aforementioned amniotic membrane's anti-inflammatory actions

may indirectly contribute to its anti-scarring actions, several lines of experimental evidence also support the notion that amniotic membrane may exert a direct anti-scarring effect on fibroblasts. Although the exact molecular candidate(s) in the amniotic membrane remains to be determined, it has been well demonstrated that the amniotic membrane stroma suppresses TGF- β signaling and myofibroblast differentiation for cultured human corneal fibroblasts and limbal fibroblasts⁴⁷ and cultured human conjunctival fibroblasts and pterygium body fibroblasts.⁴⁸ Expression of TGF- β 1 and deposition of collagen and fibronectin are reduced by amniotic membrane transplanted on excimer laser ablated corneal surface.^{49, 50} Human amniotic membrane transplantation into the rabbit corneal stromal pocket reduces the myofibroblast differentiation elicited by invading epithelial cells and in a tissue culture model of collagen gel contraction.⁵¹ These actions help explain why corneal scarring (also termed haze) is reduced in excimer laser-induced keratectomy in rabbits by amniotic membrane transplantation^{41, 41, 52-54}. Collectively, these experimental data support the notion that amniotic membrane transplantation reduces scar formation, i.e., possessing an anti-scarring effect.

- Recently, it has been reported that amniotic stromal matrix is capable of maintaining the characteristic dendritic morphology and keratocan expression of human^{55, 56}, murine⁵⁷, and monkey (manuscript submitted, 2005) keratocytes in culture while continuing expanding these cells even in the presence of serum. This unique action of amniotic membrane stroma matrix is closely linked to its effect of downregulating TGF- β signaling including downregulation of TGF- β promoter activities^{56, 57}.
- The combination of the aforementioned effects also explains why amniotic membrane has been used as an ideal substrate to cultivate epithelial progenitor cells of the conjunctiva⁵⁸⁻⁶⁰, the cornea^{62, 63}, the limbus^{61, 64-70}, the oral mucosa^{71, 72, 63}, and the corneal endothelium⁷³ *in vitro*. The resultant cultivated cells and amniotic membrane have been transplanted in normal rabbits,^{74, 71} as well as in limbal stem cell deficiency rabbit^{71, 75} and rat models, for a short-term study⁷⁶. It also has been used in limbal deficient rabbits for a long-term study⁷⁷⁻⁷⁹. Currently this composite tissue is being transplanted to restore vision as well as the structure and the function of damaged ocular surfaces in humans⁸⁰.
^{81, 82, 72}. At the present time, there are several experimental protocols used to expand limbal epithelial progenitor cells using amniotic membrane. They vary in the use of limbal epithelial explants or dispase-isolated epithelial cell suspension, the use of intact or denuded amniotic membrane, and the use of 3T3 fibroblast feeder layers. It remains unclear which protocol is most appropriate and effective in accomplishing this objective. These clinical effects are based on the premises that amniotic membrane facilitates epithelialization, prolongs epithelial stem cell survival, and reduces inflammation and scarring.

III. Clinical Uses

Clinical uses of amniotic membrane transplantation can be grossly categorized into two major modes, i.e., as a temporary graft or as a permanent graft. For the latter, it can be further categorized into two major modes, i.e., to be used alone or in conjunction with other surgical procedures.

When amniotic membrane is used as a *temporary graft*, the membrane is sutured as a bandage (lens), dressing, or patch to cover both healthy host tissue and the site of interest at the same time so that host epithelial healing heals underneath. Upon completion of epithelialization, the membrane is invariably dissolved or removed in a period varying from 2 to 6 weeks. When amniotic membrane is used as a *permanent graft*, the membrane is sutured to fill in the tissue defect of the cornea or the conjunctiva so that host cells will grow over or into the membrane and the membrane will be integrated into the host tissue.

1. As a Temporary Graft (Patch, Dressing, or Bandage)

As stated above and summarized in Fig. 1 and in a recent review^{10, 11}, AM can be used as a *temporary graft* (patch, dressing or bandage) to reduce inflammation and scarring of the ocular surface and hence reduce the pain and discomfort experienced by the patient inflicted with various diseases and insults. They include acute chemical and thermal burns of the ocular surface^{44, 83-90} which remain as one of the most devastating and challenging ophthalmic emergencies. Chemical burns, especially alkali, result in severe inflammation, which if left relentless and chronic, invariably results in granulation and scarring. Scars on the corneal surface threaten the vision, scars in the conjunctiva cause motility restriction, and scars in the lids lead to exposure, mechanical micro-trauma (by misdirected lashes and keratinization), and dryness. Conventional therapies for chemical burns have shown a limited success. AM transplantation as a temporary graft has been shown to reduce inflammation and scarring, hence facilitating wound healing and restoring comfort and vision. Thus, Pan et al⁸⁹ reported the therapeutic effect of amniotic membrane transplantation in 28 eyes with ocular burns; chemical (n=20) and thermal (n=8). In all eyes, the ocular inflammation was controlled after 3-7 days of surgery. There was corneal transparency in 16/28 eyes. All eyeballs were saved and had stable ocular surface.


AM can also be used to suppress inflammation, promote healing, and prevent scarring in patients suffering from acute Stevens Johnson syndrome (SJS) with or without toxic epidermal necrolysis (TEN) at the acute stage^{91, 92} (Kobayshi et al, 2005, in press). The conventional managements at Intensive Care and Burn Units are directed to life-threatening problems, and thus frequently are inadequate to address the ocular inflammation and ulceration. As a result, patients suffering are frequently left with a blinding disease because of scarring-induced late complications.

AM as a temporary graft can also be used to treat chronic recalcitrant inflammation with or without persistent epithelial defect caused by various diseases⁹³ including neurotrophic keratitis caused by herpes zoster virus (HZO) or herpes simplex virus (HSV)^{17, 45 94}, vernal keratoconjunctivitis^{8-10, 95, 96}. Occasionally, both a patch and

a graft are used together, and in that case the patch is used as a protective shield to ensure epithelialization of the AM used as a graft^{10, 11, 97}. Recently, AM has been advocated to promote healing and reduce inflammation in high-risk eyes receiving penetrating or lamellar keratoplasties.⁹⁴

Furthermore, in experimental rabbit models, AM as a temporary graft is effective in reducing inflammation and corneal haze induced by excimer laser ablation^{41, 41, 42, 42, 52, 98, 99}, and to improve implantation of keratoprosthesis, i.e., artificial cornea¹⁰⁰ (Fig. 3). However, as there are few reports, the clinical efficacy in human patients has not been thoroughly demonstrated. One of them is by Lee et al⁵⁴, who reported 2 patients who developed subepithelial opacities and myopic regression after photorefractive keratectomy (PRK). Both cases were treated successfully with PRK and amniotic membrane application. Dua et al¹⁰ used amniotic membrane after PRK in one patient with marked haze; repeat PRK was carried out with amniotic membrane application. The patient had minimal post-operative pain and epithelialization occurred within 5 days. The haze was reduced 50% but not enough to improve his quality of vision.

Fig. 1



Since April 2005, Bio-Tissue, Inc. has made available a sutureless AmnioGraft, termed “ProKera”, through which AmnioGraft can be delivered to the ocular surface through a symblepharon ring (conformer). Such an FDA approved medical device is most ideal for accomplishing the above objectives without sutures.

2. As a Permanent Graft

Conventionally, when amniotic membrane is used as a permanent graft, it is secured onto the ocular surface by interrupted or running sutures. New advances have been made to reduce the surgical time and to improve the outcome through the use of fibrin glue [for a review see Tseng et al, 2005].

A. For Corneal Surface Reconstruction

1) Corneal Ulcers with Different Depths Including Perforation

Corneal ulcers are serious and urgent clinical problems that can be complicated by microbial infections and threaten patient's vision. Corneal ulcers can be caused by various insults, e.g., exogenously from chemical burns, infection, radiation, or surgeries, while endogenously from aging, diabetes mellitus, viral (herpes) infection, and autoimmune disorders. Corneal ulcers are relatively uncommon and require immediate attention. When medical treatments fail and the ulceration persists (e.g., more than 3 weeks), conventional surgical treatments are usually indicated and include lamellar or full-thickness corneal transplantation (transplantation of allogenic cornea), tarsorrhaphy (closure of patient's lids) and conjunctival flap (transferring patient's own conjunctiva to cover the diseased cornea). Amniotic membrane transplantation offers the following advantages, e.g., avoidance of potential complications of corneal transplantation including allograft rejection, feasibility in lieu of cornea tissues in places where there is a shortage of cornea tissues, preservation of patient's cosmetic appearance without lid closure or covering of the cornea with a vascularized conjunctival tissue.

A total of 10 studies have been reported. All 10 reports noted that ocular surface inflammation is markedly reduced following transplantation (nearly in all cases), and the defect covered by amniotic membrane heals rapidly (1 to 4 weeks). The overall success of healing the ulcer without recurrence ranges from 67% to 91%, with an average of 78.6% (103/131 eyes). Variable success rates are attributed to differences in the underlying etiology, depths of ulceration, and accompanied treatments. Some patients regained more vision after transplantation.

Lee and Tseng¹⁰¹ first reported that amniotic membrane transplantation results in rapid healing in 3.9 ± 2.3 weeks, complete healing without recurrence in 10/11 consecutive eyes for a follow up of 9.0 ± 5.9 months. One failure case had severe rheumatoid arthritis. Kruse et al¹⁰² reported the use of multiple layers of amniotic membrane to fill in ulcers with significant depths and noted rapid healing in 4 weeks, remained stable in 9/11 eyes for 1 year. Two patients recurred due to severe neurotrophic keratopathy (loss of corneal innervation). Azuara-Blanco and Dua¹⁰³ reported complete healing in 4/5 eyes. Chen et al¹⁰⁴ reported rapid healing in 16.6 ± 9.0 days in 14/16 eyes of severe neurotrophic ulcers with varying depths for a follow up of 18.8 ± 13.0 months. The four failure cases (presumably due to more severe involvement) required tarsorrhaphy and corneal transplantation to heal the refractory ulceration. Gabric et al¹⁰⁵ reported success of healing corneal ulcers in 8/12 eyes in 1-3 weeks. Hanada et al¹⁰⁶ reported complete healing in 16.5 ± 8.0 days in 8/11 eyes using multiple layers of amniotic membrane to treat deep corneal ulcers with descemetocoele (i.e., total ulceration up to the descemet membrane) (n=5), with additional scleral ulceration (n=2), and corneal perforation (n=4). One failure eye had limbal stem cell deficiency due to chemical burns and two eyes had severe rheumatoid arthritis. Letko et al¹⁰⁷ reported successful healing of 21/30 eyes with persistent corneal epithelial defects which were refractory to contact lens and tarsorrhaphy with an average healing time of 25.5 days

after surgery. Su and Lin¹⁰⁸ reported one case report of successful treatment of corneal perforation using amniotic membrane and tissue adhesive. Heinz et al,⁹⁷ reported the successful epithelial and stromal healing in one patient with severe Graves ophthalmopathy with a corneal ulcer refractive to topical treatment and orbital decompression surgery. Rodriguez et al reported successful treatment of corneal ulcers of different sizes in 11/15 eyes (73%), by using multilayer amniotic membrane transplantation. Three of the four unsuccessful treatments were of perforations 3 mm or more in diameter. The authors concluded that multilayer AMT is effective for corneal perforations with diameter less than 1.5 mm and suggested that it may be a good alternative to penetrating keratoplasty, especially in acute cases in which graft rejection risk is high.¹⁰⁹ .¹¹⁰ reported successful management of corneal ulcers and perforations in 27/33 eyes. Perforated ulcers up to 3 mm in diameter (n=14) received fibrin glue and amniotic membrane. Ulcers healed in a mean time of 3.6 ± 1.6 weeks. Failure was noted in 6 eyes with severe neurotrophic keratitis, Stevens-Johnson syndrome, ocular cicatricial pemphigoid and Acanthamoeba keratitis.

2) Symptomatic Bullous Keratopathy

Bullous keratopathy, i.e., corneal edema, is a disorder caused by corneal endothelial decompensation due to degeneration (Fuch's endothelial dystrophy), surgical trauma, intractable glaucoma, or previous corneal graft failure. Patients with bullous keratopathy complain of ocular pain and loss of vision. For those patients with potential vision, corneal transplantation is the treatment of choice. However, for those who do not have a visual potential, relief of pain will rely on several different surgical treatments including cauterization, anterior stromal puncture, excimer laser photoablation, and conjunctival flap. Without treatment, the disease showed a progressive deterioration with persistent ocular discomfort.

Because amniotic membrane can be an ideal substrate to improve the corneal stroma, Pires et al¹¹¹ reported an overall success of 90% (43/48 eyes) of achieving a stable surface and pain relief for the follow up period of 33.8 weeks (3 – 96 weeks). Among the five failure cases, 3 received repeated amniotic membrane transplantation and one received conjunctival flap for pain relief. The amniotic membrane covered corneal surface healed with 3 weeks. Only 4 (8%) showed recurrent surface breakdown. The reconstructed corneal surface showed reduced inflammation. Espana et al¹¹² reported 88% pain relief in 18 eyes (18 patients) during a mean follow up of 25.1 months (12 to 45 months). One eye had evisceration for persistent pain 10 months postoperatively. Dua and Gomes¹⁰ have used the amniotic membrane in 16 patients with symptomatic bullous keratopathy; finding rapid epithelialization of the membrane, usually within 7 days. Post-operative pain was significantly less than pre-operative but long term follow-up results are awaited.

3) Band Keratopathy

Band keratopathy, i.e., calcium deposit on the corneal surface, occurs in a number of corneal diseases characterized by chronic inflammation and sometimes bullous

keratopathy. Patients with band keratopathy complain of ocular irritation and experience corneal surface erosion and breakdown, leading to a threat of possible microbial infection. Conventional treatments include chelation by EDTA and superficial keratectomy, i.e., removal of the superficial calcium deposit and the corneal stromal tissue. Without treatment, band keratopathy does not show any remission and instead has a slowly progressive clinical course. Anderson et al¹¹³ reported 14/15 eyes (93%) of success of using amniotic membrane transplantation to relieve patient's pain, and achieved 15/16 eyes (94%) epithelialization in an average of 15.2 days during the mean follow up period of 14.6 months. Vision improved in 5/9 sighted eyes (44%).

4) Partial Limbal Stem Cell Deficiency

The epithelial stem cells are located exclusively at the limbus, i.e., the anatomic junction between the cornea and the conjunctiva. Limbal epithelial stem cells are responsible for regeneration of the corneal epithelium, which has a rapid turnover rate. Destructive loss of the limbal epithelial stem cells and/or dysfunction of the limbal stroma will lead to limbal stem cell deficiency, which is characterized by conjunctivalization of the cornea, i.e., the conjunctival epithelium migrates to cover the corneal surface, which is accompanied by vascularization, destruction of the basement membrane, chronic inflammation, and scarring of the cornea [for cytological evidence see¹¹⁴]. Limbal stem cell deficiency can be caused by a number of corneal diseases such as chemical and thermal burns, Stevens-Johnson syndrome, ocular pemphigoid, severe microbial infections, radiation keratopathy, aniridia, etc. Patients suffer from limbal stem cell deficiency complain of severe photophobia (light sensitivity) and severe loss of vision. Without treatment, limbal stem cell deficiency is progressively worsened with time. Conventional corneal transplantation invariably fails, as no stem cells are transplanted, and frequently rejected due to corneal vascularization and inflammation. New surgical strategy resorts to autologous or allogeneic transplantation of limbal epithelial stem cells.¹¹⁵ Amniotic membrane used as a surgical graft was popularized by Kim and Tseng^{116, 117} in a rabbit model of limbal stem cell deficiency. They reported a surprising 40% success in 13 eyes, with recovery of a normal corneal epithelial phenotype as compared to 100% failure in 10 control eyes, which showed a conjunctival phenotype.

Tseng et al¹¹⁸ reported a success of 100% in 8/8 eyes with *partial* limbal stem cell deficiency, i.e., partial loss of host limbal stem cells, suggesting that amniotic membrane transplantation alone is sufficient to restore the corneal surface in this entity without the use of limbal stem cell transplantation. When the follow-up period was extended for an average of 25.8 months, Anderson et al¹¹⁹ noted that there was still an overall success of 93% of 14 sighted eyes with *partial* limbal stem cell deficiency and 86% of 17 such eyes with reduction of photophobia and pain. More recently, Sangwan et al¹²⁰ studied the efficacy of amniotic membrane transplantation in reconstructing the corneal epithelial surface and visual rehabilitation in 4 patients with partial limbal stem cell deficiency. All eyes exhibited stable corneal epithelial surface by an average of 7 weeks postoperatively and best corrected visual acuity improved an average of 4.5 lines on Snellen visual acuity charts.

C. For Conjunctival Surface Reconstruction

When a large conjunctival lesion is surgically removed, the conjunctival defect is normally healed by the surrounding conjunctiva with granulation and scarring, which may lead to disfiguring and motility restriction of the extraocular muscles or the lid blinking. To avoid such potential problems, conjunctival autograft from the same eye or the fellow eye is frequently used. However, some patients might not have healthy conjunctival tissue to spare and further removal of the uninvolved conjunctiva might put the patient at additional risks. De Roth¹²¹ in 1940 first used *live* fetal membrane (i.e., amnion plus chorion) for conjunctival surface reconstruction during symblepharon lysis (i.e., to release the adhesion between the bulbar and the tarsal conjunctival surface). Probably due to the inclusion of chorion and his use of live tissue, the success rate of 1/6 eyes was not impressive.

Based on the aforementioned improved method of preparation and preservation, amniotic membrane transplantation has been used for conjunctival surface reconstruction. In general, studies showed that the defect covered by amniotic membrane heals rapidly, and the resultant surface is less inflamed with minimal scarring in those cases with a success.

1) Conjunctivochalasis

Conjunctivochalasis is defined as a conjunctival redundancy, frequently seen in the older age group as an elevation of the bulbar conjunctiva lying along the lower lid margin¹²²; but not restricted to it, as described by Di Pascuale et al¹²³. Conjunctivochalasis can cause a spectrum of symptoms, ranging from aggravation of a dry eye at the mild stage, to disturbance of tear outflow at the moderate stage, and exposure problems at the severe stage. For symptomatic patients, topical lubricants can be tried, but they are frequently unsuccessful, and surgical excision may be required. Meller et al¹²⁴ reported successful reconstruction of conjunctival surface following the removal of conjunctivochalasis, i.e., redundant conjunctiva, in 46/47 consecutive eyes (98%) with resolution of ocular irritation. Complications included focal inflammation of the host conjunctiva adjacent to the amniotic membrane graft (6 eyes), scar formation (5 eyes), and suture-induced granuloma (1 eye). Georgiadis et al¹²⁵ reported resolution of symptoms in 12 patients with chronic epiphora caused by conjunctivochalasis, after removal of the excess of conjunctiva followed by amniotic membrane transplantation; during a mean follow-up of 8 months.

2) Tumors

Amniotic membrane transplantation has been used in for conjunctival surface reconstruction when a large lesion is removed. In general, studies showed that the defect covered by amniotic membrane heals rapidly, and the resultant surface is less inflamed with minimal scarring in those cases with a success.

Tseng et al¹²⁶ first reported successful reconstruction in 11/17 eyes (65%) with removal of melanoma (n=1), melanosis (n=1), conjunctivochalasis (n=1), conjunctival intraepithelial neoplasia (n=3), conjunctival scarring without symblepharon (n=3), and conjunctival scarring with symblepharon (n= 8) in a follow up period of 10.9 ± 9.1 months. The defect covered by amniotic membrane healed in 3 weeks. In three of such patients, impression cytology confirmed the restoration of a normal conjunctival epithelial phenotype with goblet cells.¹²⁷ Paridaens et al¹²⁸ reported successful reconstruction of conjunctival surface in 3/4 eyes (75%) following the removal of malignant melanoma and primary acquired melanosis with atypia with amniotic membrane transplantation. Chen et al¹²⁹ referred amniotic membrane transplantation as a very effective method to repair wound after conjunctival tumor removal in 26 patients (26 eyes) including 9 eyes with malignant tumors (conjunctival melanoma, corneal and conjunctival squamous cell carcinoma and conjunctival lymphoma), 17 eyes with benign tumors (conjunctival papilloma, conjunctival nevus, etc.). Dalla et al¹³⁰ reported successful reconstruction of conjunctival surface in 4/4 patients with diffuse conjunctival melanoma after a minimum follow-up of 48 months.

3) Glaucoma Surgery / Leaking Bleb

The anti-inflammatory and anti-scarring effects of amniotic membrane prompted Barton et al¹³¹ to investigate in rabbits the efficacy of maintaining glaucoma filtration procedure. Fujishima et al¹³² reported the success of maintaining trabeculectomy using amniotic membrane transplantation in conjunction with 0.4 mg/ml of mitomycin C application. Budenz et al¹³³ reported in a randomized and prospective clinical study that amniotic membrane grafts achieved the same pressure-lowering effect in repairing leaking glaucoma filtering blebs as conjunctival advancement surgery in a mean follow up of 19 months. However, the cumulative survival rate for amniotic membrane graft was 81% at 6 months and 46% in 2 years compared to 100% for conjunctival advancement procedure. Gomez and Dua¹⁰ have reported very different results from one and other regarding the use of amniotic membrane in glaucoma surgery. While Gomez using the amniotic membrane transplantation in 4 patients (4 eyes) presenting post-trabeculectomy with mitomycin C complications (leaking blebs), noticed completed resolution of the problem. Dua used it in 2 patients to cover the exposed pericardial patch, which was used to cover the tube of a valve implant and in both patients the amniotic membrane underwent necrosis, and was replaced with an autologous conjunctival patch with good results.

4) Scleral Melt

Rodriquez-Ares et al¹³⁴ reported a single case of successful reconstruction of conjunctival surface and sclera in a patient with Marfan's syndrome with extensive scleral defect.

5) Pterygium

Pterygium is a common eye disease caused by chronic exposure to ultraviolet light. Pterygium is a disease characterized by progressive fibrovascular proliferation of the stroma and the dysfunction of the adjacent limbal epithelial stem cells. The mainstay of therapy remains to be surgical. Following the removal of pterygium by a bare sclera technique, the denuded conjunctival surface is left either uncovered or covered with a graft. For the former without a graft, adjunctive therapies such as topical application of mitomycin C or external beta irradiation is needed to reduce the recurrence rate, which is otherwise quite high. These two adjunctive therapies are associated with such complications as scleral melt and microbial infections. For the latter with a graft, the conventional graft used is conjunctival autograft, where a part of free conjunctival tissue is taken from the same eye or the uninvolved fellow eye and used to cover the conjunctival defect. The use of conjunctival autograft is however limited in patients with more than one pterygium in the eye, or in patients with recurrent pterygium after several excisions or following previous conjunctival autograft, or in patients with glaucoma where the donor site is reserved for the prospective filtering procedure. For all of these clinical situations, amniotic membrane may be used as an alternative graft.

The following 8 studies used amniotic membrane transplantation for conjunctival surface reconstruction following removal of primary or recurrent pterygium. For primary pterygium, Prabhasawat et al¹³⁵ first compared a prospective study using amniotic membrane grafts (n=54) to a retrospective study using conjunctival autografts (n=122) in both primary and recurrent pterygium. They noted that the recurrence rate is 10.9% using amniotic membrane grafts, which is still higher than 2.6% of conjunctival grafts. Nevertheless, both results of amniotic membrane grafts and conjunctival autografts are significantly better than the primary closure (n=20), which resulted in 45% high recurrence rate for primary pterygium. Subsequently, Solomon et al¹³⁶ reported that by incorporating a larger removal of subconjunctival fibrous tissue and injection of long-acting steroid, amniotic membrane grafts achieved a lower recurrence rate of 3.0%, compatible with 2.6% of conjunctival autografts published by Prabhasawat et al.¹³⁵ Kim et al¹³⁷ reported a recurrence rate of 18% in 11 primary pterygium. Ma et al¹³⁸ reported 3.7% recurrence rate in 80 eyes using amniotic membrane grafts, which is compatible with 5.4% of 56 eyes with conjunctival autografts, and 3.7% of 54 eyes with topical mitomycin C, an anti-metabolite that inhibits cell proliferation, in primary pterygium. Ang et al^{129, 139} compared the use of autologous cultivated conjunctival transplantation and conventional amniotic membrane transplantation for the treatment of primary pterygium in 40 patients. Patients were divided in 2 groups, A and B respectively. Complete epithelialization was achieved 5 days after surgery in group A and approx 3 weeks after the surgery in group B. After a mean follow-up of 14.1 months (12 to 25 months) the recurrence rate was 22.7% in group A and 25.0% in group B. They only noticed one ocular complication, affecting a patient in group B who developed scleral necrosis associated with a persistent epithelial defect.

Recurrent pterygium represents a more aggressive disease. In the study conducted by Prabhasawat et al¹³⁵, the recurrence rate is 37.5% for recurrent pterygium, which is much higher than 9.5% using conjunctival autografts for recurrent pterygium. Gabric et al¹⁰⁵ reported a 30% recurrence in 10 eyes with recurrent pterygium using amniotic

membrane grafts. Subsequently, Solomon et al¹³⁶ reported that by incorporating a larger removal of subconjunctival fibrous tissue and injection of long-acting steroid, amniotic membrane grafts achieved a lower recurrence rate of 9.5%, which was compatible with 9.5% using conjunctival autografts for recurrent pterygium reported by Prabhasawat et al.¹³⁵ As recurrent pterygium frequently receives more than one surgery and there is a great deal of shortage of normal conjunctival adjacent to the diseased area, it is theoretically advantageous to add a conjunctival autograft, which will bring in some healthy conjunctival epithelial stem cells. The size of this conjunctival autograft is much smaller than that normally used without amniotic membrane transplantation. Using this new approach, Kim et al¹³⁷ reported that no recurrence in 9 eyes with recurrent pterygium, and Shimazaki et al¹⁴⁰ reported no recurrence in 4 eyes with recurrent pterygium. Kawasaki et al¹⁴¹ reported a 12% recurrence in 26 eyes with recurrent pterygium. The mean follow-up time was 17.3 +/- 9.3 months. All patients were operated on with an extensive excision of the subconjunctival fibrous tissues followed by application of mitomycin C (0.04%, 3-5 min) during the operation. Amniotic membrane transplantation was performed with implantation of conjunctival autograft in cases with large excision. Ma et al¹⁴² compared the efficacy and safety of amniotic membrane graft alone (n=48) and combined with intraoperative mitomycin C (0.025%, 3 min) (n=46) after excision of recurrent pterygium, in 95 patients. No significant difference in the recurrence rate between the two groups was found after a mean follow-up of 12 months. In the AMT group, 6 conjunctival (12.5%) and 6 corneal (12.5%) recurrences developed. In the AMT-mitomycin group 4 conjunctival (8.5%) and 6 corneal (12.5%) recurrences developed.

6) Symblepharon and Fornix Reconstruction

For cases of symblepharon; i.e., scar in the conjunctiva causing motility restriction, the main goal is to achieve a deep fornix and lack of motility restriction. Azuara-Blanco and Dua¹⁰³ reported that a successful reconstruction of one case with symblepharon. Gabric et al¹⁰⁵ reported success of conjunctival reconstruction in 5/6 eyes with conjunctival scarring. Honavar et al¹⁴³ reported successful fornix reconstruction in 9/10 eyes with symblepharon in patients with Stevens-Johnson syndrome in a mean follow up period of 13.5 ± 3.8 months. The complete healing took 1 to 6 weeks. Solomon et al¹⁴⁴ reported complete fornix reconstruction in 12/17 eyes (70.6%) of 15 patients with symblepharon due to a variety of ocular disorders, after a mean follow-up of 37 +/- 24 months (9-84 months). In eyes that demonstrated partial success or failure, the underlying etiology was either an autoimmune disorder or a recurrent pterygium. Barabino et al¹⁴⁵ reported the improvement of the ocular surface condition, with reacquired fornix depth, and reduced inflammation in one patient with late stage ocular cicatricial pemphigoid. Later on, Barabino et al¹⁴⁶ reported successful symblepharon lysis in 5/9 eyes (9 patients) with advanced ocular cicatricial pemphigoid, during a mean follow-up of 48 weeks (28-96 weeks). Katircioglu et al¹⁴⁷ reported successful fornix reconstruction in 5/6 eyes in patients with symblepharon due to chemical burns in a mean follow-up of 10 +/- 7.37 months (4-24 months). Jain et al¹⁴⁸ noticed the effectiveness of the AMT in the surgical treatment of symblepharon in 12/20 eyes of 18 patients. Zhou et al¹⁴⁹ reported successful fornix reconstruction in 31/55 eyes after a mean follow-up of 27 +/- 2.6 months (26-30 months). Tseng et al¹⁵⁰ used intraoperative application of

mitomycin C (0.04% for 5 minutes) to reduce chronic conjunctival inflammation, helping amniotic membrane to restore a deep fornix after symblepharon lysis in 18 eyes (16 patients) suffering from various diseases. They reported successful fornix reconstruction in 15/18 eyes after a mean follow-up of 14.16 ± 5.2 months. Nava-Castaneda et al^{149, 151} reported better conjunctival fornix reconstruction with the simultaneous combination of AM and mitomycin C than with the use of AM alone.

D. For Both Corneal and Conjunctival Surface Reconstruction

Amniotic membrane can also be used for treating cicatrizing conditions involving the both the corneal and conjunctival surfaces. For example, in eyes with chemical burns involving the conjunctival and sectorial corneal surface with pannus, amniotic membrane can be used for symblepharon lysis, fornix reconstruction of the conjunctival region while at the same time, part of amniotic membrane can be extended to cover the corneal surface where the pannus is removed by superficial keratectomy.

E. In Conjunction with Other Surgical Procedures

As mentioned before, amniotic membrane transplantation alone is sufficient to restore corneal surfaces that have partial limbal stem cell deficiency (i.e., with some remaining healthy stem cells) in human patients.^{118, 119} Nevertheless when used in conjunction with other surgical procedures to provide some epithelial stem cells, amniotic membrane transplantation is effective to restore the ocular surface in patients with severe ocular disorders.

A total of 7 studies have been reported using amniotic membrane with or without limbal stem cell transplantation for reconstructing the corneal surface with limbal stem cell deficiency. The overall success depends on the severity of the limbal stem cell deficiency, i.e., partial versus total, accompanied corneal diseases, and severity of the ocular surface illness, such as dry eye. For *partial* limbal stem cell deficiency, amniotic membrane transplantation is a superior alternative as it alone without limbal stem cell transplantation is sufficient to restore the corneal surface and improve the vision in a majority of the patients. For unilateral *total* limbal stem cell deficiency, autologous limbal stem cell transplantation can be performed in conjunction with amniotic membrane transplantation.¹⁵² Thus, amniotic membrane transplantation augments the success of limbal stem cell transplantation. The overall success of the procedure is very high. For bilateral *total* limbal stem cell deficiency, allogeneic limbal stem cell transplantation is needed to restore such damaged cornea^{90, 149}. The overall success is further influenced by the survival of this limbal allograft (see below for more details).

1) With Conjunctival Limbal Autograft or Allograft

Shimazaki et al⁸⁵ reported successful reconstruction of corneal surface damaged by chemical and thermal burns in 7/7 eyes (100%) using amniotic membrane

transplantation and limbal stem cell transplantation of an autologous (n=4) and allogeneic (n=2) source in a mean follow up period of 53.3 weeks. Later on, Shimazaki et al¹⁵³ reported successful treatment in 23/27 eyes (85.2%) with recurrent pterygium by using amniotic membrane transplantation combined either with limbal autograft transplantation (n=15) or conjunctival autograft transplantation (n=12), after a mean follow-up of 67.0 weeks. Gomes et al¹⁵⁴ reported satisfactory ocular surface reconstruction in 15/20 eyes (75%) with chemical burns with limbal stem cell deficiency, using amniotic membrane transplantation with or without limbal transplantation from either autologous or allogeneic source, after a mean follow-up of 19 months (8-27months). Success was observed in all cases of partial limbal stem cell deficiency and in 68.75% (11 eyes) of cases of total limbal stem cell deficiency. Meallet et al¹⁵⁵ reported successful corneal surface reconstruction in 5 eyes (5 patients) with total limbal stem cell deficiency, using conjunctival limbal autograft combined with amniotic membrane transplantation on both the donor and recipient eyes. During the mean follow-up of 22 months (11-48 months) all eyes experienced symptomatic relief. All recipient eyes had a mean improvement in visual acuity of nine lines (range 7-12). The donor eyes showed rapid healing and restoration of the normal limbal landmark. Gomes et al¹⁵⁶ reported only 20% (2/10 eyes) success in ocular surface reconstruction in 10 patients with total limbal stem cells and conjunctival deficiency secondary to Stevens-Johnson syndrome, after a mean follow-up of 16.7 months. Patients underwent excision of cicatricial tissue followed by amniotic membrane and living related corneal/limbal conjunctival transplantation. Yao et al¹⁵⁷ reported the successful approach for treating multirecurrent pterygia with severe symblepharon by combining intraoperative mitomycin C, amniotic membrane and limbal conjunctival autograft in 6/7 eyes (7 patients), for a mean follow-up of 22.4 ± 6.1 months. Miyai et al^{153, 158} describe the use of limbal allograft, preserved amniotic membrane transplantation, and intraoperative mitomycin C, as a safe and effective procedure for treating recurrent pterygium. They evaluate 12 eyes of 11 patients. After a mean follow-up period of 21.6 ± 5.6 months, there was no pterygium recurrence, symblepharon recurred in 3 eyes and diplopia in 2 eyes. Santos et al^{153, 159} reported the usefulness of the conjunctival limbal grafts associated with AMT for restoring corneal epithelial phenotype in 33 eyes of 31 patients with total LSCD. They also describe dry eye as the most important prognostic parameter. However, they found that the cumulative survival declines substantially over a 2-year period.

2) With Keratolimbal Allograft

Tsubota et al reported successful reconstruction of the corneal surface in 12/14 eyes (86%) with *total* limbal stem cell deficiency due to severe and advanced ocular pemphigoid and Stevens-Johnson syndrome using amniotic membrane transplantation in conjunction with keratolimbal allograft in a mean follow up period of 143 days. In children with Stevens-Johnson syndrome Tsubota et al¹⁶⁰ reported successful reconstruction in 3/5 eyes using amniotic membrane transplantation and keratolimbal allograft. Tseng et al¹¹⁸ confirmed that amniotic membrane transplantation needed to be combined with keratolimbal allograft when there was a total loss of limbal epithelial stem cells. In a total of 21 eyes (n=7 without additional corneal transplantation; n=14 with

additional corneal transplantation), they noted successful corneal surface reconstruction of 71% and 79%, respectively, in a mean follow-up period of 15.4 months. When the follow-up period was extended to an average of 1163 days (over 3 years), Tsubota et al¹⁶¹ noted that in their large series of 43 eyes with *total* limbal stem cell deficiency, the overall success rate is reduced to 51% due to progressive allograft rejection of the keratolimbal transplant despite amniotic membrane transplantation. Another major limiting factor to the success of such corneal surface reconstruction is the presence of severe aqueous tear deficiency, i.e., dry eye.¹⁶² Espana et al¹⁶³ did a phenotypic study of a case receiving a keratolimbal allograft and amniotic membrane for a total stem cell deficiency, finding a normal corneal epithelial phenotype with normal base membrane complexes. Jurowski et al¹⁶⁴ reported good results in 3 eyes (2 patients) with chemical (acid) burns. Shimazaki et al¹⁶⁵ described their findings in 32 eyes (32 patients) with chemical burns associated with total limbal dysfunction. Patients were treated by amniotic membrane transplantation combined either with conjunctivolimbal autograft transplantation (n=11) or keratolimbal allograft transplantation (n=21). At final examination, 17 eyes (53.1%) showed stable corneal epithelialization. The autograft group showed significantly better results than the allograft group in both corneal epithelialization and clear cornea.

IV. Complications

There have not been any report showing microbial infections directly linked with amniotic membrane transplantation. Kim et al¹³⁷ reported such complications as submembrane hemorrhage (3/25 eyes, 12%) and early detachment of the membrane (1/25, 4%). The former is obviously related to the surgery and not amniotic membrane. Gabler and Lohmann¹⁶⁶ reported a case who developed sterile hypopyon (inflammation inside the anterior chamber) following repeated transplantation of amniotic membrane. They attributed this complication to immunologic, toxic or hypersensitive effect of the membrane. No similar complication has been reported by others.

Marangon et al¹⁶⁷ reported the incidence and characteristics of post-AMT infections of a total of 326 patients undergoing AMT from January 1994 to February 2001 at the Bascom Palmer Eye Institute. They subdivided these patients in 2 groups related to the submission or not of the AMT storage media for culture under an institutional Review Board-approval protocol. 11 culture positive infections (3.4%) were identified. 7 (9.2%) were from the first group and 4 (1.6%) were from the second group. All infections occurring within 1 month after AMT (n=4) were exclusively from the first group. All AM storage media from the second group were culture negative. Gram-positive organisms were the most frequent isolated (64%). Finally they concluded that AMT is a safe method for ocular surface reconstruction with a very low rate of microbial infections, especially if AM is prepared according to Good Tissue Banking Practice set forth by FDA.

Gomez¹⁰ observed a granulomatous reaction, unrelated to sutures, a few days after ocular surface reconstruction combined with a living related conjunctival limbal allograft in a Stevens-Johnson syndrome patient.

V. Other Issues

Since amniotic membrane was introduced for the management of ocular surface disorders, it has been harvested, prepared in many different ways. The earliest report in ophthalmology, dating 1940 is by De Roth, who used fresh membrane, including both, chorion and amnion, as a dressing in patients with conjunctival defects. Laverly and Sorsby in 1946 and Symmons in 1947 used an “amnioplastin graft”, a chemically processed dry amniotic membrane, in the treatment of patients with chemical burns. In 1993 Batle and Perdomo reported the use of alcohol-preserved AM (Russian Method). Over the years the tissue-processing techniques have evolved; thus in 1995, Kim and Tseng reported the use of cryopreserved AM in a rabbit model. Since then it has been a great development of the amniotic membrane in ophthalmic surgery.^{10, 11, 15} Although a freeze-dried AM is used, it has not been approved by FDA as a surgical graft (see FDA website: <http://www.fda.gov/cber/compl/ambio062305.htm>). Finally, it should be noted that fresh amniotic membrane is still commonly used outside the US.¹⁶⁸⁻¹⁷² The use of fresh amniotic membrane is not approved by FDA in USA.

Literature Citation:

1. Mast BA, Diegelmann RF, Krummel TM, Cohen IK. Scarless wound healing in mammalian fetus. *Surgery*. 1992;174:441-451.
2. Adzick NS, Lorenz HP. Cells, matrix, growth factors, and the surgeon. The biology of scarless fetal wound repair. *Ann Surg*. 1994;220:10-18.
3. Tseng SCG, Kim JC, Meller D, et al. Amniotic membrane transplantation for ocular surface reconstruction. *Hong Kong J Ophthalmol*. 1998;2:26-34.
4. Dua HS, Azuara-Blanco A. Amniotic membrane transplantation. *Br J Ophthalmol*. 1999;83:748-752.
5. Markuszewska J, Krzyzanowska P. Amniotic membrane transplantation (AMT) for ocular surface reconstruction. *Klin Oczna*. 1999;101:311-316.
6. Solomon A, Tseng SCG. [Amniotic membrane transplantation for ocular surface diseases]. *Harefuah*. 2000;139:134-140.
7. Kruse FE, Meller D. [Amniotic membrane transplantation for reconstruction of the ocular surface]. *Ophthalmologe*. 2001;98:801-810.
8. Sippel KC, Ma JJK, Foster CS. Amniotic membrane surgery. *Curr Opin Ophthalmol*. 2001;12:269-281.
9. Tseng SCG. Amniotic membrane transplantation for ocular surface reconstruction. *Bioscience Rep*. 2002;21:481-489.
10. Dua HS, Gomes JA, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. *Surv Ophthalmol*. 2004;49:51-77.
11. Bouchard CS, John T. Amniotic Membrane Transplantation in the Management of Severe Ocular Surface Disease: Indications and Outcomes. *The Ocular Surface*. 2004;2:201-211.
12. Datta H, Sarkar K, Chatterjee PR. Amniotic membrane transplantation in ocular surface disorders. *J Indian Med Assoc*. 2004;102:726-729.

13. Burman S, Tejwani S, Vemuganti GK, Gopinathan U, Sangwan VS. Ophthalmic applications of preserved human amniotic membrane: a review of current indications. *Cell Tissue Bank*. 2004;5:161-175.
14. Tosi GM, Massaro-Giordano M, Caporossi A, Toti P. Amniotic membrane transplantation in ocular surface disorders. *J Cell Physiol*. 2005;202:849-851.
15. Fernandes M, Sridhar MS, Sangwan VS, Rao GN. Amniotic membrane transplantation for ocular surface reconstruction. *Cornea*. 2005;24:643-653.
16. Gomes JA, Romano A, Santos MS, Dua HS. Amniotic membrane use in ophthalmology. *Curr Opin Ophthalmol*. 2005;16:233-240.
17. Kenyon KR. Amniotic membrane: mother's own remedy for ocular surface disease. *Cornea*. 2005;24:639-642.
18. Tseng SCG, Espana EM, Kawakita T, et al. How does amniotic membrane work? *The Ocular Surface*. 2004;2:177-187.
19. Fukuda K, Chikama T, Nakamura M, Nishida T. Differential distribution of subchains of the basement membrane components type IV collagen and laminin among the amniotic membrane, cornea, and conjunctiva. *Cornea*. 1999;18:73-79.
20. Lei H, Kalluri R, Furth EE, Baker AH, Strauss JF, III. Rat amnion type IV collagen composition and metabolism: implications for membrane breakdown. *Biol Reprod*. 1999;60:176-182.
21. Endo K, Nakamura T, Kawasaki S, Kinoshita S. Human amniotic membrane, like corneal epithelial basement membrane, manifests the alpha5 chain of type IV collagen. *Invest Ophthalmol Vis Sci*. 2004;45:1771-1774.
22. Kurpakus-Wheater M. Laminin-5 is a component of preserved amniotic membrane. *Curr Eye Res*. 2001;22:353-357.
23. Boudreau N, Werb Z, Bissell MJ. Suppression of apoptosis by basement membrane requires three-dimensional tissue organization and withdrawal from the cell cycle. *Proc Natl Acad Sci USA*. 1996;93:3500-3513.
24. Weaver VM, Bissell M. Functional culture models to study mechanisms governing apoptosis in normal and malignant mammary epithelial cells. *J Mammary Gland Bio Neoplasia*. 1999;4:193-201.
25. Cooper LJ, Kinoshita S, German M, Koizumi N, Nakamura T, Fullwood NJ. An investigation into the composition of amniotic membrane used for ocular surface reconstruction. *Cornea*. 2005;24:722-729.
26. Aplin JD, Campbell S. The extracellular matrix of human amniotic epithelium: ultrastructure, composition and deposition. *J Cell Sci*. 1985;79:119-136.
27. Modesti A, Kalebic T, Scarpa S, et al. Type V collagen in human amnion is a 12 nm fibrillar component of the pericellular interstitium. *Eur J Cell Biol*. 1984;35:246-255.
28. Yeh LK, Chen WL, Li W, et al. Soluble lumican glycoprotein purified from human amniotic membrane promotes corneal epithelial wound healing. *Invest Ophthalmol Vis Sci*. 2005;46:479-486.
29. Koizumi N, Inatomi T, Sotozono C, Fullwood NJ, Quantock AJ, Kinoshita S. Growth factor mRNA and protein in preserved human amniotic membrane. *Curr Eye Res*. 2000;20:173-177.
30. Hao Y, Ma DH-K, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. *Cornea*. 2000;19:348-352.
31. Ma DH, Yao JY, Yeh LK, et al. In vitro antiangiogenic activity in ex vivo expanded human limbal corneal epithelial cells cultivated on human amniotic membrane. *Invest Ophthalmol Vis Sci*. 2004;45:2586-2595.
32. Na BK, Hwang JH, Kim JC, et al. Analysis of human amniotic membrane components as proteinase inhibitors for development of therapeutic agent of recalcitrant keratitis. *Trophoblast Res*. 1999;13:459-466.

33. el Maradny E, Kanayama N, Halim A, Maehara K, Terao T. Urinary trypsin inhibitor has a protective effect on the amnion. *Gynecol Obstet Invest.* 1994;38:169-172.
34. Kobayashi H, Sun GW, Terao T. Urinary trypsin inhibitor down-regulates hyaluronic acid fragment-induced prostanoid release in cultured human amnion cells by inhibiting cyclo-oxygenase-2 expression. *Mol Human Repr.* 1999;5:662-667.
35. Uchida S, Inanaga Y, Kobayashi M, Hurukawa S, Araie M, Sakuragawa N. Neurotrophic function of conditioned medium from human amniotic epithelial cells. *J Neurosci Res.* 2000;62:585-590.
36. Touhami A, Grueterich M, Tseng SC. The role of NGF signaling in human limbal epithelium expanded by amniotic membrane culture. *Invest Ophthalmol Vis Sci.* 2002;43:987-994.
37. Trautman MS, Collmer D, Edwin SS, White W, Mitchell MD, Dudley DJ. Expression of interleukin-10 in human gestational tissues. *J Soc Gynecol Invest.* 1997;4:247-253.
38. Paradowska E, Blach-Olszewska Z, Gejdel E. Constitutive and induced cytokine production by human placenta and amniotic membrane at term. *Placenta.* 1997;18:441-446.
39. Shao C, Sima J, Zhang SX, et al. Suppression of corneal neovascularization by PEDF release from human amniotic membranes. *Invest Ophthalmol Vis Sci.* 2004;45:1758-1762.
40. Solomon A, Rosenblatt M, Monroy DC, Ji Z, Pflugfelder SC, Tseng SCG. Suppression of Interleukin-1 α and Interleukin-1 β in the human corneal epithelial cells cultured on the amniotic membrane matrix. *Br J Ophthalmol.* 2001;85:444-449.
41. Wang MX, Gray TB, Parks WC, et al. Corneal haze and apoptosis is reduced by amniotic membrane matrix in excimer laser photoablation in rabbits. *J Cat Refract Surg.* 2001;27:310-319.
42. Park WC, Tseng SCG. Modulation of acute inflammation and keratocyte death by suturing, blood and amniotic membrane in PRK. *Invest Ophthalmol Vis Sci.* 2000;41:2906-2914.
43. Shimmura S, Shimazaki J, Ohashi Y, Tsubota K. Antiinflammatory effects of amniotic membrane transplantation in ocular surface disorders. *Cornea.* 2001;20:408-413.
44. Kim JS, Kim JC, Na BK, Jeong JM, Song CY. Amniotic membrane patching promotes healing and inhibits protease activity on wound healing following acute corneal alkali burns. *Exp Eye Res.* 1998;70:329-337.
45. Heiligenhaus A, Meller D, Meller D, Steuhl K-P, Tseng SCG. Improvement of HSV-1 necrotizing keratitis with amniotic membrane transplantation. *Invest Ophthalmol Vis Sci.* 2001;42:1969-1974.
46. Li W, He H, Kawakita T, Espana EM, Tseng SCG. Amniotic membrane induces apoptosis of interferon-gamma activated macrophages in vitro. *Exp Eye Res.* 2005; In Press.
47. Tseng SCG, Li D-Q, Ma X. Suppression of Transforming Growth Factor isoforms, TGF- β receptor II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. *J Cell Physiol.* 1999;179:325-335.
48. Lee S-B, Li D-Q, Tan DTH, Meller D, Tseng SCG. Suppression of TGF- β signaling in both normal conjunctival fibroblasts and pterygial body fibroblasts by amniotic membrane. *Curr Eye Res.* 2000;20:325-334.
49. Zhong Y, Zhou Y, Wang K. [The preliminary study of amniotic membrane on TGF-beta 1 expression after photorefractive keratectomy]. *Yan Ke Xue Bao.* 1999;15:215-7, 235.
50. Zhong Y, Zhai Z, Zhou Y, Ye W, Wang K. [Effect of amniotic membrane on expressions of TGF-beta 1, collagens I, III and fibronectin in rabbit corneal healing after photorefractive keratectomy]. *Yan Ke Xue Bao.* 2000;16:239-42, 258.

51. Choi TH, Tseng SCG. *In vivo* and *in vitro* demonstration of epithelial cell-induced myofibroblast differentiation of keratocytes and an inhibitory effect by amniotic membrane. *Cornea*. 2001;20:197-204.
52. Choi YS, Kim JY, Wee WR, Lee JH. Effect of the application of human amniotic membrane on rabbit corneal wound healing after excimer laser photorefractive keratectomy. *Cornea*. 1998;17:389-395.
53. Woo H-M, Kim MS, Kweon O-K, Kim D-Y, Nam T-C, Kim JH. Effects of amniotic membrane on epithelial wound healing and stromal remodelling after excimer laser keratectomy in rabbit cornea. *Br J Ophthalmol*. 2001;85:345-349.
54. Lee HK, Kim JK, Kim EK, Kim GO, Lee IS. Phototherapeutic keratectomy with amniotic membrane for severe subepithelial fibrosis following excimer laser refractive surgery. *J Cataract Refract Surg*. 2003;29:1430-1435.
55. Espana EM, He H, Kawakita T, et al. Human keratocytes cultured on amniotic membrane stroma preserve morphology and express keratocan. *Invest Ophthalmol Vis Sci*. 2003;44:5136-5141.
56. Espana EM, Kawakita T, Liu CY, Tseng SCG. CD-34 expression by cultured human keratocytes is downregulated during myofibroblast differentiation induced by TGF-beta1. *Invest Ophthalmol Vis Sci*. 2004;45:2985-2991.
57. Kawakita T, Espana EM, He H, et al. Keratocan expression of murine keratocytes is maintained on amniotic membrane by downregulating TGF-beta signaling. *J Biol Chem*. 2005;In Press.
58. Cho B-J, Djalilian AR, Obritsch WF, Matteson DM, Chan CC, Holland EJ. Conjunctival epithelial cells cultured on human amniotic membrane fail to transdifferentiate into corneal epithelial-type cells. *Cornea*. 1999;18:216-224.
59. Meller D, Tseng SCG. Conjunctival epithelial cell differentiation on amniotic membrane. *Invest Ophthalmol Vis Sci*. 1999;40:878-886.
60. Meller D, Dabul V, Tseng SC. Expansion of conjunctival epithelial progenitor cells on amniotic membrane. *Exp Eye Res*. 2002;74:537-545.
61. Sangwan VS, Vemuganti GK, Singh S, Balasubramanian D. Successful reconstruction of damaged ocular outer surface in humans using limbal and conjunctival stem cell culture methods. *Biosci Rep*. 2003;23:169-174.
62. Koizumi N, Fullwood NJ, Bairaktaris G, Inatomi T, Kinoshita S, Quantock AJ. Cultivation of corneal epithelial cells on intact and denuded human amniotic membrane. *Invest Ophthalmol Vis Sci*. 2000;41:2506-2513.
63. Kinoshita S, Nakamura T. Development of cultivated mucosal epithelial sheet transplantation for ocular surface reconstruction. *Artif Organs*. 2004;28:22-27.
64. Schwab IR, Reyes M, Isseroff RR. Successful transplantation of bioengineered tissue replacements in patients with ocular surface disease. *Cornea*. 2000;19:421-426.
65. Koizumi N, Cooper LJ, Fullwood NJ, et al. An evaluation of cultivated corneal limbal epithelial cells, using cell-suspension culture. *Invest Ophthalmol Vis Sci*. 2002;43:2114-2121.
66. Meller D, Pires RTF, Tseng SCG. Ex vivo preservation and expansion of human limbal epithelial stem cells on amniotic membrane cultures. *Br J Ophthalmol*. 2002;86:463-471.
67. Grueterich M, Tseng SCG. Human limbal progenitor cells expanded on intact amniotic membrane. *Arch Ophthalmol*. 2002;120:783-790.
68. Grueterich M, Espana E, Tseng SC. Connexin 43 expression and proliferation of human limbal epithelium on intact and denuded amniotic membrane. *Invest Ophthalmol Vis Sci*. 2002;43:63-71.
69. Ban Y, Cooper LJ, Fullwood NJ, et al. Comparison of ultrastructure, tight junction-related protein expression and barrier function of human corneal epithelial cells

- cultivated on amniotic membrane with and without air-lifting. *Exp Eye Res.* 2003;76:735-743.
70. Ramaesh K, Dhillon B. Ex vivo expansion of corneal limbal epithelial/stem cells for corneal surface reconstruction. *Eur J Ophthalmol.* 2003;13:515-524.
 71. Nakamura T, Endo K, Cooper LJ, et al. The successful culture and autologous transplantation of rabbit oral mucosal epithelial cells on amniotic membrane. *Invest Ophthalmol Vis Sci.* 2003;44:106-116.
 72. Nakamura T, Inatomi T, Sotozono C, Amemiya T, Kanamura N, Kinoshita S. Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders. *Br J Ophthalmol.* 2004;88:1280-1284.
 73. Ishino Y, Sano Y, Nakamura T, et al. Amniotic membrane as a carrier for cultivated human corneal endothelial cell transplantation. *Invest Ophthalmol Vis Sci.* 2004;45:800-806.
 74. Koizumi N, Inatomi T, Quantock AJ, Fullwood NJ, Dota A, Kinoshita S. Amniotic membrane as a substrate for cultivating limbal corneal epithelial cells for autologous transplantation in rabbits. *Cornea.* 2000;19:65-71.
 75. Nakamura T, Kinoshita S. Ocular surface reconstruction using cultivated mucosal epithelial stem cells. *Cornea.* 2003;22:S75-S80.
 76. Song E, Yang W, Cui ZH, et al. Transplantation of human limbal cells cultivated on amniotic membrane for reconstruction of rat corneal epithelium after alkaline burn. *Chin Med J (Engl).* 2005;118:927-935.
 77. Ti SE, Anderson D, Touhami A, Kim C, Tseng SC. Factors affecting outcome following transplantation of ex vivo expanded limbal epithelium on amniotic membrane for total limbal deficiency in rabbits. *Invest Ophthalmol Vis Sci.* 2002;43:2584-2592.
 78. Espana EM, Ti SE, Grueterich M, Touhami A, Tseng SC. Corneal stromal changes following reconstruction by ex vivo expanded limbal epithelial cells in rabbits with total limbal stem cell deficiency. *Br J Ophthalmol.* 2003;87:1509-1514.
 79. Ti SE, Grueterich M, Espana EM, Touhami A, Anderson DF, Tseng SC. Correlation of long term phenotypic and clinical outcomes following limbal epithelial transplantation cultivated on amniotic membrane in rabbits. *Br J Ophthalmol.* 2004;88:422-427.
 80. Nakamura T, Koizumi N, Tsuzuki M, et al. Successful re-grafting of cultivated corneal epithelium using amniotic membrane as a carrier in severe ocular surface disease. *Cornea.* 2003;22:70-71.
 81. Tan DT, Ang LP, Beuerman RW. Reconstruction of the ocular surface by transplantation of a serum-free derived cultivated conjunctival epithelial equivalent. *Transplantation.* 2004;77:1729-1734.
 82. Nakamura T, Inatomi T, Sotozono C, Koizumi N, Kinoshita S. Successful primary culture and autologous transplantation of corneal limbal epithelial cells from minimal biopsy for unilateral severe ocular surface disease. *Acta Ophthalmol Scand.* 2004;82:468-471.
 83. Sorsby A, Symons HM. Amniotic membrane grafts in caustic burns of the eye. *Br J Ophthalmol.* 1946;30:337-345.
 84. Sorsby A, Haythorne J, Reed H. Further experience with amniotic membrane grafts in caustic burns of the eye. *Br J Ophthalmol.* 1947;31:409-418.
 85. Shimazaki J, Yang H-Y, Tsubota K. Amniotic membrane transplantation for ocular surface reconstruction in patients with chemical and thermal burns. *Ophthalmology.* 1997;104:2068-2076.
 86. Meller D, Pires RTF, Mack RJS, et al. Amniotic membrane transplantation for acute chemical or thermal burns. *Ophthalmology.* 2000;107:980-990.

87. Sridhar MS, Bansal AK, Sangwan VS, Rao GN. Amniotic membrane transplantation in acute chemical and thermal injury. *Am J Ophthalmol.* 2000;130:134-137.
88. Kobayashi A, Shirao Y, Yoshita T, et al. Temporary amniotic membrane patching for acute chemical burns. *Eye.* 2003;17:149-158.
89. Pan DP, Li XX, Xu JF. [Therapeutic effect of amniotic membrane transplantation for ocular burn]. *Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi.* 2003;17:318-320.
90. Muraine M. [Amniotic-membrane and limbic stem-cell transplantation in the management of ocular burns]. *J Fr Ophthalmol.* 2004;27:1179-1190.
91. John T, Foulks GN, John ME, Cheng K, Hu D. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. *Ophthalmology.* 2002;109:351-360.
92. Di Pascuale MA, Espana EM, Liu DT, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. *Ophthalmology.* 2005;112:904-912.
93. Kim JC. Use of temporary amniotic membrane graft for corneal diseases. In: 1998:49.
94. Kenyon KR. Neurotrophic keratitis: current management strategies. *An Inst Barraquer (Barc).* 2003;32:173-174.
95. Sridhar MS, Sangwan VS, Bansal AK, Rao GN. Amniotic membrane transplantation in the management of shield ulcers of vernal keratoconjunctivitis. *Ophthalmology.* 2001;108:1218-1222.
96. Kruse FE, Rohrschneider K, Voelcker HE. Transplantation von amnio-membran zur rekonstruktion der hornhautoberfläche. *Ophthalmologe.* 1999;96:673-678.
97. Heinz C, Eckstein A, Steuhl KP, Meller D. Amniotic membrane transplantation for reconstruction of corneal ulcer in graves ophthalmopathy. *Cornea.* 2004;23:524-526.
98. Hong JW, Kang SM, Kim HJ, Kim HM. The effect of phototherapeutic keratectomy (PTK)-photorefractive keratectomy (PRK)- amniotic membrane transplantation (AMT) on myopic regression with corneal opacity after PRK in high myopia. In. 39 ed.; 1998:S354.
99. Kim JY, Wee WR, Choi YS, Lee JH. Clinical outcome of photorefractive keratectomy (PRK) retreatment using amniotic membrane. *Ophthalmology.* 1998:162.
100. Kaminski SL, Lacombe E, Duchesne B, et al. Supradescemetic keratoprosthesis (SD-Kpro): A novel design. *Invest Ophthalmol Vis Sci.* 2002;43:2993.
101. Lee S-H, Tseng SCG. Amniotic membrane transplantation for persistent epithelial defects with ulceration. *Am J Ophthalmol.* 1997;123:303-312.
102. Kruse FE, Rohrschneider K, Völcker HE. Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. *Ophthalmology.* 1999;106:1504-1511.
103. Azuara-Blanco A, Pillai CT, Dua HS. Amniotic membrane transplantation for ocular surface reconstruction. *Br J Ophthalmol.* 1999;8339:399-402.
104. Chen H-J, Pires RTF, Tseng SCG. Amniotic membrane transplantation for severe neurotrophic corneal ulcers. *Br J Ophthalmol.* 2000;84:826-833.
105. Gabric N, Mravicic I, Dekaris I, Karaman Z, Mitrovic S. Human amniotic membrane in the reconstruction of the ocular surface. *Doc Ophthalmol.* 1999;98:273-283.
106. Hanada K, Shimazaki J, Shimmura S, Tsubota K. Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera. *Am J Ophthalmol.* 2001;131:324-331.
107. Letko E, Stechschulte SU, Kenyon KR, et al. Amniotic membrane inlay and overlay grafting for corneal epithelial defects and stromal ulcers. *Arch Ophthalmol.* 2001;119:659-663.
108. Su CY, Lin CP. Combined use of an amniotic membrane and tissue adhesive in treating corneal perforation: a case report. *Ophthalmic Surg Lasers.* 2000;31:151-154.

109. Rodriguez-Ares MT, Tourino R, Lopez-Valladares MJ, Gude F. Multilayer amniotic membrane transplantation in the treatment of corneal perforations. *Cornea*. 2004;23:577-583.
110. Hick S, Demers PE, Brunette I, La C, Mabon M, Duchesne B. Amniotic membrane transplantation and fibrin glue in the management of corneal ulcers and perforations: a review of 33 cases. *Cornea*. 2005;24:369-377.
111. Pires RTF, Tseng SCG, Prabhasawat P, et al. Amniotic membrane transplantation for symptomatic bullous keratopathy. *Arch Ophthalmol*. 1999;117:1291-1297.
112. Espana EM, Grueterich M, Sandoval H, et al. Amniotic membrane transplantation for bullous keratopathy in eyes with poor visual potential. *J Cat Refract Surg*. 2003;in press.
113. Anderson DF, Prabhasawat P, Alfonso E, Tseng SCG. Amniotic membrane transplantation after the primary surgical management of band keratopathy. *Cornea*. 2001;20:354-361.
114. Puangsrichareern V, Tseng SCG. Cytologic evidence of corneal diseases with limbal stem cell deficiency. *Ophthalmology*. 1995;102:1476-1485.
115. Tseng SCG. Regulation and clinical implications of corneal epithelial stem cells. *Mol Biol Rep*. 1996;23:47-58.
116. Kim JC, Tseng SCG. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. *Cornea*. 1995;14:473-484.
117. Kim JC, Tseng SCG. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. *Korean J Ophthalmol*. 1995;9:32-46.
118. Tseng SCG, Prabhasawat P, Barton K, Gray T, Meller D. Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency. *Arch Ophthalmol*. 1998;116:431-441.
119. Anderson DF, Ellies P, Pires RT, Tseng SC. Amniotic membrane transplantation for partial limbal stem cell deficiency. *Br J Ophthalmol*. 2001;85:567-575.
120. Sangwan VS, Matalia HP, Vemuganti GK, Rao GN. Amniotic membrane transplantation for reconstruction of corneal epithelial surface in cases of partial limbal stem cell deficiency. *Indian J Ophthalmol*. 2004;52:281-285.
121. de Roth A. Plastic repair of conjunctival defects with fetal membrane. *Arch Ophthalmol*. 1940;23:522-525.
122. Francis IC, Chan DG, Kim P, et al. Case-controlled clinical and histopathological study of conjunctivochalasis. *Br J Ophthalmol*. 2005;89:302-305.
123. Di Pascuale MA, Espana EM, Kawakita T, Tseng SC. Clinical characteristics of conjunctivochalasis with or without aqueous tear deficiency. *Br J Ophthalmol*. 2004;88:388-392.
124. Meller D, Maskin SL, Pires RTF, Tseng SCG. Amniotic membrane transplantation for symptomatic conjunctivochalasis refractory to medical treatments. *Cornea*. 2000;19:796-803.
125. Georgiadis NS, Terzidou CD. Epiphora caused by conjunctivochalasis: treatment with transplantation of preserved amniotic membrane. *Cornea*. 2001;20:619-621.
126. Tseng SCG, Prabhasawat P, Lee S-H. Amniotic membrane transplantation for conjunctival surface reconstruction. *Am J Ophthalmol*. 1997;124:765-774.
127. Prabhasawat P, Tseng SCG. Impression cytology study of epithelial phenotype of ocular surface reconstructed by preserved human amniotic membrane. *Arch Ophthalmol*. 1997;115:1360-1367.
128. Paridaens D, Beekhuis H, van Den Bosch W, Remeyer L, Melles G. Amniotic membrane transplantation in the management of conjunctival malignant melanoma and primary acquired melanosis with atypia. *Br J Ophthalmol*. 2001;85:658-661.

129. Chen Z, Yan J, Yang H, et al. Amniotic membrane transplantation for conjunctival tumor. *Yan Ke Xue Bao*. 2003;19:165-7, 145.
130. Dalla PG, Ghirlando A, Busato F, Midena E. Reconstruction of conjunctiva with amniotic membrane after excision of large conjunctival melanoma: a long-term study. *Eur J Ophthalmol*. 2005;15:446-450.
131. Barton K, Budenz D, Khaw PT, Tseng SCG. Glaucoma filtration surgery using amniotic membrane transplantation. *Invest Ophthalmol Vis Sci*. 2001;42:1762-1768.
132. Fujishima H, Shimazaki J, Shinozaki N, Tsubota K. Trabeculectomy with the use of amniotic membrane for uncontrolled glaucoma. *Ophthalmic Surg Lasers*. 1998;29:428-431.
133. Budenz DL, Barton K, Tseng SCG. Amniotic membrane transplantation for repair of leaking glaucoma filtering blebs. *Am J Ophthalmol*. 2000;130:580-588.
134. Rodriguez-Ares MT, Tourino R, Capeans C, Sanchez-Salorio M. Repair of scleral perforation with preserved scleral amniotic membrane in Marfan's syndrome. *Ophthalmic Surg Lasers*. 1999;30:485-487.
135. Prabhasawat P, Barton K, Burkett G, Tseng SCG. Comparison of conjunctival autografts, amniotic membrane grafts and primary closure for pterygium excision. *Ophthalmology*. 1997;104:974-985.
136. Solomon A, Pires RTF, Tseng SCG. Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia. *Ophthalmology*. 2001;108:449-460.
137. Kim JC, Lee D, Shyn KH. Clinical uses of human amniotic membrane for ocular surface diseases. In: Lass JH (ed), *Advances in Corneal Research* New York: Plenum Press; 1997:117-134.
138. Ma DH-K, See L-C, Liao S-B, Tsai RJF. Amniotic membrane graft for primary pterygium: comparison with conjunctival autograft and topical mitomycin C treatment. *Br J Ophthalmol*. 2000;84:973-978.
139. Ang LP, Tan DT, Cajucom-Uy H, Beuerman RW. Autologous cultivated conjunctival transplantation for pterygium surgery. *Am J Ophthalmol*. 2005;139:611-619.
140. Shimazaki J, Shinozaki N, Tsubota K. Transplantation of amniotic membrane and limbal autograft for patients with recurrent pterygium associated with symblepharon. *Br J Ophthalmol*. 1998;82:235-240.
141. Kawasaki S, Uno T, Shimamura I, Ohashi Y. [Outcome of surgery for recurrent pterygium using intraoperative application of mitomycin C and amniotic membrane transplantation]. *Nippon Ganka Gakkai Zasshi*. 2003;107:316-321.
142. Ma DH, See LC, Hwang YS, Wang SF. Comparison of amniotic membrane graft alone or combined with intraoperative mitomycin C to prevent recurrence after excision of recurrent pterygia. *Cornea*. 2005;24:141-150.
143. Honavar SG, Bansal AK, Sangwan VS, Rao GN. Amniotic membrane transplantation for ocular surface reconstruction in Stevens-Johnson syndrome. *Ophthalmology*. 2000;107:975-979.
144. Solomon A, Espana EM, Tseng SCG. Amniotic membrane transplantation for reconstruction of the conjunctival fornices. *Ophthalmology*. 2003;110:93-100.
145. Barabino S, Rolando M. Amniotic membrane transplantation elicits goblet cell repopulation after conjunctival reconstruction in a case of severe ocular cicatricial pemphigoid. *Acta Ophthalmol Scand*. 2003;81:68-71.
146. Barabino S, Rolando M, Bentivoglio G, et al. Role of amniotic membrane transplantation for conjunctival reconstruction in ocular-cicatricial pemphigoid. *Ophthalmology*. 2003;110:474-480.

147. Katircioglu YA, Budak K, Salvarli S, Duman S. Amniotic membrane transplantation to reconstruct the conjunctival surface in cases of chemical burn. *Jpn J Ophthalmol.* 2003;47:519-522.
148. Jain S, Rastogi A. Evaluation of the outcome of amniotic membrane transplantation for ocular surface reconstruction in symblepharon. *Eye.* 2004;18:1251-1257.
149. Zhou SY, Chen JQ, Chen LS, Liu ZG, Huang T, Wang ZC. [Long-term results of amniotic membrane transplantation for conjunctival surface reconstruction]. *Zhonghua Yan Ke Za Zhi.* 2004;40:745-749.
150. Tseng SCG, Di Pascuale MA, Liu D-Z, GAO Y-Y, Baradaran-Rafii A. Intraoperative mitomycin C and amniotic membrane transplantation for fornix reconstruction in severe cicatricial ocular surface diseases. *Ophthalmology.* 2005;112:896-903.
151. Nava-Castaneda A, Tovila-Canales JL, Monroy-Serrano MH, et al. [Comparative study of amniotic membrane transplantation, with and without simultaneous application of mitomycin C in conjunctival fornix reconstruction]. *Arch Soc Esp Oftalmol.* 2005;80:345-352.
152. Pires RTF, Chokshi A, Tseng SCG. Amniotic membrane transplantation or limbal conjunctival autograft for limbal stem cell deficiency induced by 5- fluorouracil in glaucoma surgeries. *Cornea.* 1999;19:284-287.
153. Shimazaki J, Kosaka K, Shimmura S, Tsubota K. Amniotic membrane transplantation with conjunctival autograft for recurrent pterygium
1. *Ophthalmology.* 2003;110:119-124.
154. Gomes JA, dos Santos MS, Cunha MC, Mascaro VL, Barros JN, de Sousa LB. Amniotic membrane transplantation for partial and total limbal stem cell deficiency secondary to chemical burn. *Ophthalmology.* 2003;110:466-473.
155. Meallet MA, Espana EM, Grueterich M, Ti S-E, Goto E, Tseng SCG. Amniotic membrane transplantation for recipient and donor eyes undergoing conjunctival limbal autograft for total limbal stem cell deficiency. *Ophthalmology.* 2003;110:1585-1592.
156. Gomes JA, Santos MS, Ventura AS, Donato WB, Cunha MC, Hofling-Lima AL. Amniotic membrane with living related corneal limbal/conjunctival allograft for ocular surface reconstruction in Stevens-Johnson syndrome. *Arch Ophthalmol.* 2003;121:1369-1374.
157. Yao YF, Qiu WY, Zhang YM, Tseng SC. Mitomycin C, amniotic membrane transplantation and limbal conjunctival autograft for treating multirecurrent pterygia with symblepharon and motility restriction. *Graefes Arch Clin Exp Ophthalmol.* 2005;1-5.
158. Miyai T, Hara R, Nejima R, Miyata K, Yonemura T, Amano S. Limbal allograft, amniotic membrane transplantation, and intraoperative mitomycin C for recurrent pterygium. *Ophthalmology.* 2005;112:1263-1267.
159. Santos MS, Gomes JA, Hofling-Lima AL, Rizzo LV, Romano AC, Belfort R, Jr. Survival analysis of conjunctival limbal grafts and amniotic membrane transplantation in eyes with total limbal stem cell deficiency. *Am J Ophthalmol.* 2005;140:223-230.
160. Tsubota K, Satake Y, Ohyama M, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome. *Am J Ophthalmol.* 1996;122:38-52.
161. Tsubota K, Satake Y, Kaido M, et al. Treatment of severe ocular surface disorders with corneal epithelial stem-cell transplantation. *N Eng J Med.* 1999;340:1697-1703.
162. Shimazaki J, Shimmura S, Fujishima H, Tsubota K. Association of preoperative tear function with surgical outcome in severe Stevens-Johnson syndrome. *Ophthalmology.* 2000;107:1518-1523.

163. Espana EM, Grueterich M, Ti SE, Tseng SC. Phenotypic study of a case receiving a keratolimbal allograft and amniotic membrane for total limbal stem cell deficiency. *Ophthalmology*. 2003;110:481-486.
164. Jurowski P, Gos I. [Keratolimbal allografts and multilayer amniotic membrane transplantation in the treatment of ocular surface disease due to chemical burns]. *Klin Oczna*. 2004;106:648-652.
165. Shimazaki J, Shimmura S, Tsubota K. Donor source affects the outcome of ocular surface reconstruction in chemical or thermal burns of the cornea. *Ophthalmology*. 2004;111:38-44.
166. Gabler B, Lohmann CP. Hypopyon after repeated transplantation of human amniotic membrane onto the corneal surface. *Ophthalmology*. 2000;107:1344-1346.
167. Marangon FB, Alfonso EC, Miller D, REmonda NM, Muallem MS, Tseng SCG. Incidence of microbial infection after amniotic membrane transplantation. *Cornea*. 2004;23:264-269.
168. Luo HY, Peng SM, Wang YJ. [Fresh amniotic membrane transplantation for ocular surface diseases]. *Di Yi Jun Yi Da Xue Xue Bao*. 2003;23:488-489.
169. Zhou SY, Chen JQ, Liu ZG, Huang T, Chen LS. [A clinical study of amniotic membrane transplantation for severe eye burns at the acute stage]. *Zhonghua Yan Ke Za Zhi*. 2004;40:97-100.
170. Yang R, Wang F, Sun N. [Application of fresh amniotic membrane transplantation in treatment of stenosis of conjunctival sac]. *Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi*. 2004;18:277-280.
171. Arora R, Mehta D, Jain V. Amniotic membrane transplantation in acute chemical burns. *Eye*. 2005;19:273-278.
172. Gunduz K, Ucakhan OO, Kanpolat A, Gunalp I. Nonpreserved human amniotic membrane transplantation for conjunctival reconstruction after excision of extensive ocular surface neoplasia. *Eye*. 2005.